# Candidate Identity and Structural Verification Report: ANALOGUE_0011

**Audit Target:** `ANALOGUE_0011`  
**Parent Candidate:** `PARENT_A1` (`results/high_activity_candidate_audit.csv`, rank 1)  
**Project:** DrugGEN–BACE1/BBB Joint Optimization  
**Date of Audit:** October 2026  
**Auditor:** Computational Medicinal Chemist & Model Validation Specialist  

---

## 1. Executive Identification Summary

`ANALOGUE_0011` was generated during the bounded molecular optimization experiment in Track A. It derives directly from parent candidate `PARENT_A1` via a single, site-specific aromatic mono-fluorination at position 4 of the terminal heteroaromatic ring.

- **Candidate ID:** `ANALOGUE_0011`
- **Parent ID:** `PARENT_A1` (Audit Rank 1 in 50k baseline pool)
- **Canonical SMILES:** `CC(C)(C)COc1cnc2c(c1)C1(COC(N)=N1)c1cc(-c3cncnc3F)ccc1O2`
- **Parent Canonical SMILES:** `CC(C)(C)COc1cnc2c(c1)C1(COC(N)=N1)c1cc(-c3cncnc3)ccc1O2`
- **Transformation Operator:** Halogen Scan — Aromatic C-H -> C-F mono-fluorination (site 4 on terminal pyrimidine ring)

---

## 2. Physicochemical Descriptors and Verification

All molecular descriptors were independently recalculated from scratch using RDKit (v2026.03.6):

| Descriptor | Parent (`PARENT_A1`) | Candidate (`ANALOGUE_0011`) | Difference (Delta) | Analytical Status |
|:---|:---:|:---:|:---:|:---:|
| **Canonical Formula** | `C23H23N5O3` | **`C23H22FN5O3`** | -H, +F | Verified |
| **Exact Molecular Weight** | 417.179 g/mol | **435.171 g/mol** | +17.992 g/mol | Verified |
| **Average Molecular Weight** | 417.47 g/mol | **435.46 g/mol** | +17.99 g/mol | Verified |
| **Heavy Atom Count** | 31 | **32** | +1 atom (F) | Verified |
| **Formal Charge** | 0 | **0** | 0 | Neutral |
| **Hydrogen Bond Donors (HBD)** | 1 | **1** | 0 | Exocyclic -NH2 |
| **Hydrogen Bond Acceptors (HBA)** | 8 | **8** | 0 | Lipinski ideal |
| **Topological Polar Surface Area (TPSA)** | 104.74 Å² | **104.74 Å²** | 0.00 Å² | Unchanged polar area |
| **Calculated LogP (Crippen MolLogP)** | 3.66 | **3.80** | **+0.14** | F increases lipophilicity |
| **Rotatable Bonds** | 3 | **3** | 0 | Low conformational entropy |
| **Quantitative Drug-Likeness (QED)** | 0.693 | **0.624** | -0.069 | Favorable (>0.5) |
| **Lipinski Rule-of-Five Violations** | 0 | **0** | 0 | Fully compliant |
| **Chiral Centers** | 1 (unassigned spiro) | **1 (unassigned spiro)** | 0 | Unchanged 2D racemate |

### Discrepancy Note from Prior Report
The previous preliminary report erroneously stated the chemical formula as `C24H24FN5O2` in line 118 due to a typographical counting error. Independent recalculation establishes the correct molecular formula as **`C23H22FN5O3`** (23 carbons, 22 hydrogens, 1 fluorine, 5 nitrogens, 3 oxygens).

---

## 3. Atom-Mapped Structural Difference Analysis

An atom-mapped Maximum Common Substructure (MCS) calculation between `PARENT_A1` and `ANALOGUE_0011` was performed:
1. **Core Overlap:** The MCS contains **31 heavy atoms**, exactly matching the 31 heavy atoms of `PARENT_A1`.
2. **Ring Integrity:** All 5 rings (neopentyl-substituted pyridine, chroman core, spiro-oxazoline, central benzene, and terminal pyrimidine) retain identical atom types, hybridization, connectivity, and bond orders.
3. **Sole Modification:** Exactly one atom in `ANALOGUE_0011` is unmatched by the MCS: atom index 27, which corresponds to the **fluorine atom (F)** attached to carbon 4 of the terminal pyrimidine ring.
4. **Stereochemical Consistency:** Neither canonicalization nor reaction transformation altered the stereochemical definition. The spiro quaternary center at carbon 12 (`C1(COC(N)=N1)`) remains unspecified in both compounds.

**Verdict on Molecular Identity:** Verified with 100% precision. `ANALOGUE_0011` is strictly the mono-fluorinated derivative of `PARENT_A1`.
